The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis B Get access Arrow
Alexandra Johnson Valiente, Kin Seng Liem, Kathleen B Schwarz, Philip Rosenthal, Karen F Murray, Douglas Mogul, Jeffery Teckman, Norberto Rodriguez-Baez, Sarah Jane Schwarzenberg, Jordan J Feld, David K Wong, Lia L Lewis-Ximenez, Georg Lauer, Bettina E Hansen, Simon C Ling, Harry L A Janssen, Adam J Gehring
The Journal of Infectious Diseases, Volume 225, Issue 3, 1 February 2022, Pages 470–475, https://doi.org/10.1093/infdis/jiab373
Published:
21 July 2021
Article history
Cite
Permissions Icon Permissions
Share
Abstract
Liver damage in hepatitis B is immune driven and correlates with inflammatory markers in patient serum. There is no comparison of these markers to determine if inflammatory profiles are distinct to different types of liver damage across patients at different stages of disease. We measured 25 inflammatory markers in patients with acute hepatitis B and chronic hepatitis B with hepatitis B e antigen seroconversion and chronic patients stopping nucleoside analogue therapy. Myeloid markers dominated the inflammatory profile in all stages of hepatitis B. More inflammatory markers were detectable in chronic patients, including elevated concentrations of cytotoxic effectors Fas ligand, TRAIL, and TNF-α.
inflammation, biomarker, immune response, flare, hepatitis B, HBV, plasma, cytokines, chemokines
Topic:
cytokine tumor necrosis factors inflammatory markers inflammation chemokines hepatitis b hepatitis b e antigens hepatitis b, chronic plasma hepatitis b virus liver damage nucleoside analog tumor necrosis factor ligand superfamily member 6 acute type b viral hepatitis seroconversion